Annual Cash & Cash Equivalents
$235.26 M
-$177.82 M-43.05%
31 December 2022
Summary:
Mirati Therapeutics annual cash & cash equivalents is currently $235.26 million, with the most recent change of -$177.82 million (-43.05%) on 31 December 2022. During the last 3 years, it has fallen by -$177.82 million (-43.05%).MRTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$258.72 M
+$128.85 M+99.22%
30 September 2023
Summary:
Mirati Therapeutics quarterly cash and cash equivalents is currently $258.72 million, with the most recent change of +$128.85 million (+99.22%) on 30 September 2023.MRTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -43.0% | -37.4% |
| 5 y5 years | +405.6% | +456.0% |
MRTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -73.4% | -70.8% |
Mirati Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $258.72 M(+99.2%) |
| June 2023 | - | $129.87 M(-46.3%) |
| Mar 2023 | - | $241.93 M(+2.8%) |
| Dec 2022 | $235.26 M(-43.0%) | $235.26 M(-21.3%) |
| Sept 2022 | - | $298.84 M(+12.5%) |
| June 2022 | - | $265.60 M(-12.8%) |
| Mar 2022 | - | $304.70 M(-26.2%) |
| Dec 2021 | $413.08 M(-53.4%) | $413.08 M(+70.3%) |
| Sept 2021 | - | $242.62 M(-13.6%) |
| June 2021 | - | $280.72 M(-14.8%) |
| Mar 2021 | - | $329.50 M(-62.8%) |
| Dec 2020 | $885.56 M(+1803.0%) | $885.56 M(+573.8%) |
| Sept 2020 | - | $131.43 M(-0.2%) |
| June 2020 | - | $131.69 M(-35.6%) |
| Mar 2020 | - | $204.50 M(+339.5%) |
| Dec 2019 | $46.53 M(+42.3%) | $46.53 M(-49.4%) |
| Sept 2019 | - | $91.90 M(-63.5%) |
| June 2019 | - | $252.09 M(+237.9%) |
| Mar 2019 | - | $74.61 M(+128.2%) |
| Dec 2018 | $32.69 M(-69.6%) | $32.69 M(-72.0%) |
| Sept 2018 | - | $116.71 M(+10.1%) |
| June 2018 | - | $105.96 M(+415.2%) |
| Mar 2018 | - | $20.57 M(-80.9%) |
| Dec 2017 | $107.70 M(+381.2%) | $107.70 M(+418.2%) |
| Sept 2017 | - | $20.78 M(+4.2%) |
| June 2017 | - | $19.95 M(-32.9%) |
| Mar 2017 | - | $29.76 M(+32.9%) |
| Dec 2016 | $22.38 M(-54.8%) | $22.38 M(+13.0%) |
| Sept 2016 | - | $19.80 M(-19.3%) |
| June 2016 | - | $24.54 M(-29.0%) |
| Mar 2016 | - | $34.55 M(-30.2%) |
| Dec 2015 | $49.49 M(+650.7%) | $49.49 M(-55.0%) |
| Sept 2015 | - | $109.88 M(+721.3%) |
| June 2015 | - | $13.38 M(-6.5%) |
| Mar 2015 | - | $14.31 M(+117.0%) |
| Dec 2014 | $6.59 M | $6.59 M(+34.1%) |
| Sept 2014 | - | $4.92 M(-42.3%) |
| June 2014 | - | $8.52 M(+2.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $8.32 M(-41.6%) |
| Dec 2013 | $14.23 M(-22.6%) | $14.23 M(+86.9%) |
| Sept 2013 | - | $7.62 M(-21.8%) |
| June 2013 | - | $9.74 M(-11.4%) |
| Mar 2013 | - | $10.99 M(-40.3%) |
| Dec 2012 | $18.40 M(+87.0%) | $18.40 M(+226.5%) |
| Sept 2012 | - | $5.64 M(-30.1%) |
| June 2012 | - | $8.06 M(+46.7%) |
| Mar 2012 | - | $5.49 M(-44.2%) |
| Dec 2011 | $9.84 M(+33.7%) | $9.84 M(+21.2%) |
| Sept 2011 | - | $8.12 M(+8.2%) |
| June 2011 | - | $7.50 M(+28.6%) |
| Mar 2011 | - | $5.84 M(-20.7%) |
| Dec 2010 | $7.36 M(-45.8%) | $7.36 M(-21.1%) |
| Sept 2010 | - | $9.33 M(-19.9%) |
| June 2010 | - | $11.65 M(+11.4%) |
| Mar 2010 | - | $10.46 M(-22.9%) |
| Dec 2009 | $13.57 M(+177.7%) | $13.57 M(-3.5%) |
| Sept 2009 | - | $14.06 M(+69.9%) |
| June 2009 | - | $8.27 M(-46.8%) |
| Mar 2009 | - | $15.56 M(+218.5%) |
| Dec 2008 | $4.89 M(+50.8%) | $4.89 M(-48.7%) |
| Sept 2008 | - | $9.52 M(-63.6%) |
| June 2008 | - | $26.13 M(+17.2%) |
| Mar 2008 | - | $22.30 M(+588.4%) |
| Dec 2007 | $3.24 M(+455.3%) | $3.24 M(-93.6%) |
| Sept 2007 | - | $50.62 M(+239.2%) |
| June 2007 | - | $14.92 M(-57.4%) |
| Mar 2007 | - | $35.07 M(+5911.5%) |
| Dec 2006 | $583.40 K(+27.8%) | $583.40 K(-97.7%) |
| Sept 2006 | - | $25.83 M(-18.5%) |
| June 2006 | - | $31.71 M(+119.9%) |
| Mar 2006 | - | $14.42 M(+3059.2%) |
| Dec 2005 | $456.60 K(>+9900.0%) | $456.60 K(-91.0%) |
| Sept 2005 | - | $5.08 M(-36.9%) |
| June 2005 | - | $8.05 M(-18.4%) |
| Mar 2005 | - | $9.86 M |
| Dec 2004 | $1700.00(-19.0%) | - |
| Dec 2003 | $2100.00 | - |
FAQ
- What is Mirati Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Mirati Therapeutics?
What is Mirati Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of MRTX is $235.26 M
What is the all time high annual cash & cash equivalents for Mirati Therapeutics?
Mirati Therapeutics all-time high annual cash & cash equivalents is $885.56 M
What is Mirati Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MRTX is $258.72 M
What is the all time high quarterly cash and cash equivalents for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly cash and cash equivalents is $885.56 M